Intuitive Surgical
ISRG
$482.22
+0.71%
Intuitive Surgical Inc. is a global leader in robotic-assisted minimally invasive surgery, primarily through its da Vinci surgical system. The company operates as a dominant platform player in the medical instruments industry, with its business model encompassing the sale of robotic systems, high-margin instruments and accessories, and recurring service revenue. The current investor narrative is dominated by robust underlying business growth, as evidenced by strong recent quarterly results, juxtaposed against significant regulatory and product safety concerns highlighted by an FDA warning, creating a debate between the company's entrenched competitive moat and potential near-term headwinds.…
ISRG
Intuitive Surgical
$482.22
Related headlines
ISRG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $626.89 and implied upside of +30.0% versus the current price.
Average Target
$626.89
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$386 - $627
Analyst target range
Analyst coverage is robust with 11 firms providing estimates, and the recent institutional rating actions show a mix of reaffirmed bullish stances and a notable upgrade from Citigroup to 'Buy' in March 2026, indicating underlying confidence. The consensus recommendation leans bullish, though specific Buy/Hold/Sell distribution and an average target price are not provided in the dataset, preventing a calculation of implied upside or downside from the current price. The target price range can be inferred from revenue estimates, with the average forecast for the next period at $18.89 billion, bracketed by a low of $18.07 billion and a high of $19.96 billion, suggesting analysts see a potential variance in growth outcomes. The high-end estimate likely assumes continued market share gains, successful navigation of regulatory concerns, and strong adoption of new systems, while the low-end may factor in competitive pressures or a more pronounced impact from the recent FDA safety flag.
Bulls vs Bears: ISRG Investment Factors
The investment debate for ISRG centers on the tension between its exceptional, cash-generative fundamental business and its extreme valuation, which is being tested by technical breakdown and regulatory concerns. Currently, the bear case has stronger near-term evidence, as the stock's severe underperformance, high volatility, and premium valuation in the face of a concrete FDA warning have overwhelmed robust underlying financials. The single most important factor is whether the company can navigate the regulatory overhang without a material impact on procedure growth, thereby justifying its forward P/E of 41x. If growth remains intact, the bull case of a dominant platform prevails; if not, multiple compression will likely continue.
Bullish
- Dominant Platform with Robust Growth: ISRG's Q4 2025 revenue grew 18.8% YoY to $2.87B, driven by the high-margin Instruments & Accessories segment ($1.66B). This demonstrates the strength of its razor-and-blades model and continued procedure volume growth.
- Exceptional Profitability & Cash Flow: The company boasts a net margin of 28.4% and a gross margin of 66.44%. It generated $2.49B in TTM free cash flow, providing ample resources for R&D and growth without financial leverage, as evidenced by a debt-to-equity ratio of 0.017.
- Fortress Balance Sheet: With a current ratio of 4.87 and virtually no debt, ISRG has a fortress-like financial position. This provides significant resilience to navigate regulatory headwinds and invest counter-cyclically.
- Strong Forward Earnings Growth Priced In: The forward P/E of 41.06x is a significant discount to the trailing P/E of 70.78x, implying the market expects EPS to grow to $16.55. This compression reflects confidence in future earnings expansion despite recent price weakness.
Bearish
- Extreme Valuation Premium: ISRG's trailing P/E of 70.78x and forward P/E of 41.06x command a massive premium over typical medical device peers (20x-30x). The PEG ratio of 3.17 indicates growth expectations are extremely high and priced in, leaving little room for error.
- Severe Technical Downtrend & Underperformance: The stock is down 12.3% over 3 months and 2.8% over 1 year, significantly underperforming the S&P 500 (+2.67% and +34.9%). Trading at 78% of its 52-week range ($427.84-$603.88) shows persistent selling pressure and negative momentum.
- Regulatory & Product Safety Headwinds: The recent FDA safety flag concerning a surgical stapler introduces a tangible near-term risk. This could impact procedure volumes, trigger costly remediation, and damage the brand's reputation for safety, which is critical in healthcare.
- High Volatility Amplifies Downside: With a beta of 1.679, ISRG is ~68% more volatile than the market. This has amplified its recent -24.09% maximum drawdown and increases portfolio risk, making it unsuitable for risk-averse investors.
ISRG Technical Analysis
The stock is in a pronounced downtrend, having declined 2.80% over the past year and 12.30% over the last three months, significantly underperforming the S&P 500 which gained 34.9% and 2.67% over the same periods, respectively. Currently trading at $469.21, the price sits at approximately 78% of its 52-week range ($427.84 to $603.88), indicating it is closer to its lows than its highs, which may suggest a value opportunity but also reflects persistent selling pressure and negative sentiment. Recent short-term momentum shows further weakness, with the stock down 1.78% over the past month, diverging from the broader market's 7.36% gain and signaling continued relative underperformance and a lack of bullish catalysts. The stock's high beta of 1.679 indicates it is approximately 68% more volatile than the market, which has amplified its downside during this corrective phase and implies higher risk for investors. Key technical support is clearly defined at the 52-week low of $427.84, while resistance is established near the 52-week high of $603.88; a sustained breakdown below support could trigger a new leg down, whereas a recovery above the $500 level would be the first step toward challenging the downtrend. The stock's maximum drawdown of -24.09% over the observed period underscores the severity of the recent correction and the elevated volatility inherent in its price action.
Beta
1.68
1.68x market volatility
Max Drawdown
-24.1%
Largest decline past year
52-Week Range
$428-$604
Price range past year
Annual Return
-5.1%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | +2.6% | +8.7% |
| 3m | -8.0% | +3.6% |
| 6m | -11.8% | +5.4% |
| 1y | -5.1% | +30.6% |
| ytd | -14.2% | +4.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue reaching $2.87 billion, representing a strong 18.8% year-over-year increase, and the sequential quarterly trend from Q1 to Q4 2025 shows consistent top-line expansion from $2.25B to $2.87B. The growth is primarily driven by the high-margin Instruments and Accessories segment, which contributed $1.66 billion in the latest period, alongside Systems revenue of $786 million, indicating healthy adoption of new platforms and recurring procedure volume. Profitability is exceptional, with the company reporting net income of $794.8 million in Q4 2025 and a net margin of 28.4%, supported by a gross margin of 66.44% which reflects the lucrative razor-and-blades business model. Operating margins have shown stability, with the Q4 2025 operating income ratio at 30.15%, demonstrating the company's ability to convert strong revenue into substantial profits despite ongoing investments in R&D. The balance sheet is fortress-like, with a minimal debt-to-equity ratio of 0.017 and a robust current ratio of 4.87, indicating ample liquidity and virtually no financial leverage risk. The company generates significant cash flow, with trailing twelve-month free cash flow of $2.49 billion and an ROE of 16.02%, showcasing its ability to fund growth internally and deliver strong returns on shareholder equity without relying on debt.
Quarterly Revenue
$2.9B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.66%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given the company's substantial net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is elevated at 70.78x, while the forward PE is significantly lower at 41.06x, indicating the market is pricing in strong future earnings growth to justify the current multiple. Compared to typical medical device industry averages, which often range in the 20x-30x PE band, ISRG's 70.78x trailing multiple represents a substantial premium, justified by its market dominance, superior growth profile, and high-margin recurring revenue streams. Historically, the stock's own PE ratio has fluctuated widely; the current trailing PE of 70.78x is above its 2-year historical median, suggesting the market is still pricing in optimistic long-term expectations despite the recent price correction, but it has come down from peaks seen in prior quarters where it exceeded 80x. The forward PE compression to 41.06x, based on estimated EPS of $16.55, implies a PEG ratio of 3.17 when considering the company's growth rate, which remains rich and indicates high expectations are still embedded in the valuation.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~84x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ISRG's primary financial risk is not leverage or liquidity—its balance sheet is pristine—but rather its extreme dependence on sustaining high growth to justify a trailing P/E of 70.78x. A deceleration in its 18.8% YoY revenue growth would trigger significant multiple compression. Furthermore, while margins are robust, the company faces concentration risk in its da Vinci platform; any product issue, like the recent FDA stapler warning, could directly impact the high-margin Instruments & Accessories segment, which drove $1.66B in Q4 revenue.
Market & Competitive Risks: The stock trades at a substantial premium to industry averages, with a forward P/E of 41.06x versus a typical 20x-30x range for medtech, creating valuation compression risk in a rising rate environment or sector rotation. Its high beta of 1.679 makes it particularly sensitive to broad market downturns, amplifying downside. While competitive threats are often cited as long-term risks, the immediate external threat is regulatory, as the March 2026 FDA flag demonstrates, which could slow adoption and increase scrutiny.
Worst-Case Scenario: The worst-case scenario involves the FDA safety concern escalating into a broader product recall or mandatory pause for certain procedures, leading to a sharp decline in procedure volumes and instrument sales. Concurrently, a market downturn compresses growth stock multiples. This could trigger a re-rating towards the lower end of its historical valuation range, pushing the stock toward its 52-week low of $427.84. From the current price of $469.21, this represents a realistic downside of approximately -9% to that technical support level, with further downside possible if earnings estimates are cut.
